The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [31] Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease
    Betts, Keith A.
    Nunna, Sasikiran
    Kumar, Retesh
    Nie, Xiaoyu
    Fernandes, Ancilla W.
    KIDNEY MEDICINE, 2024, 6 (04)
  • [32] Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Koch, Gary
    Ouyang, John
    McQuade, Robert D.
    Blais, Jaime D.
    Czerwiec, Frank S.
    Sergeyeva, Olga
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1930 - 1942
  • [33] Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
    Li Zhou
    Yan Tian
    Liang Ma
    Wen-Ge Li
    World Journal of Clinical Cases, 2022, 10 (31) : 11500 - 11507
  • [34] Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
    Zhou, Li
    Tian, Yan
    Ma, Liang
    Li, Wen-Ge
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (31) : 11500 - 11507
  • [35] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Iijima, Hiroko
    Tada, Toshifumi
    Hashimoto, Mariko
    Nishimura, Takashi
    Kiriki, Masato
    Higashiura, Akiko
    Iwasaki, Aya
    Honda, Michino
    Nagasawa, Yasuyuki
    Yamakado, Koichiro
    JOURNAL OF MEDICAL ULTRASONICS, 2023, 50 (01) : 81 - 87
  • [36] Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
    Mueller, Roman-Ulrich
    Haas, Christian S.
    Sayer, John A.
    CLINICAL KIDNEY JOURNAL, 2018, 11 (01) : 62 - 69
  • [37] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Hiroko Iijima
    Toshifumi Tada
    Mariko Hashimoto
    Takashi Nishimura
    Masato Kiriki
    Akiko Higashiura
    Aya Iwasaki
    Michino Honda
    Yasuyuki Nagasawa
    Koichiro Yamakado
    Journal of Medical Ultrasonics, 2023, 50 : 81 - 87
  • [38] Altered Lipid Metabolism in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
    Bargagli, Matteo
    Anderegg, Manuel
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 160 - 161
  • [39] Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
    Masahiko Oguro
    Yuta Kogure
    Junichi Hoshino
    Yoshifumi Ubara
    Hiroki Mizuno
    Akinari Sekine
    Masahiro Kawada
    Keiichi Sumida
    Rikako Hiramatsu
    Eiko Hasegawa
    Masayuki Yamanouchi
    Noriko Hayami
    Tatsuya Suwabe
    Naoki Sawa
    Kenmei Takaichi
    Journal of Nephrology, 2018, 31 : 961 - 966
  • [40] Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
    Oguro, Masahiko
    Kogure, Yuta
    Hoshino, Junichi
    Ubara, Yoshifumi
    Mizuno, Hiroki
    Sekine, Akinari
    Kawada, Masahiro
    Sumida, Keiichi
    Hiramatsu, Rikako
    Hasegawa, Eiko
    Yamanouchi, Masayuki
    Hayami, Noriko
    Suwabe, Tatsuya
    Sawa, Naoki
    Takaichi, Kenmei
    JOURNAL OF NEPHROLOGY, 2018, 31 (06) : 961 - 966
12345